Sipuleucel-T in Metastatic Castration-Resistant Prostate Concert Profile Report

被引：2
|
作者：
Plosker, Greg L. [1 ]
机构：
[1] Adis Int Ltd, Auckland 0754, New Zealand
来源：
BIODRUGS | 2011年 / 25卷 / 04期
关键词：
CANCER; IMMUNOTHERAPY; MITOXANTRONE; PREDNISONE; DOCETAXEL;
D O I：
10.2165/11207140-000000000-00000
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：255 / 256
页数：2
相关论文
共 50 条
  • [41] Sequencing Systemic Therapies in Metastatic Castration-Resistant Prostate Cancer
    Liu, Jane Jijun
    Zhang, Jingsong
    CANCER CONTROL, 2013, 20 (03) : 181 - 187
  • [42] Development of sipuleucel-T: Autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer
    Sims, Robert B.
    VACCINE, 2012, 30 (29) : 4394 - 4397
  • [43] Rationing in urologic oncology: Lessons from sipuleucel-T for advanced prostate cancer
    Peppercorn, Jeffrey
    Armstrong, Andrew
    Zaas, David W.
    George, Daniel
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2013, 31 (07) : 1079 - 1084
  • [44] Drug therapies for metastatic castration-resistant prostate cancer
    El-Bahesh, Ehab
    Finianos, Antoine
    Alfaraj, Abeer
    Aragon-Ching, Jeanny B.
    FUTURE ONCOLOGY, 2015, 11 (17) : 2395 - 2403
  • [45] The obesity paradox in metastatic castration-resistant prostate cancer
    Martini, Alberto
    Shah, Qainat N.
    Waingankar, Nikhil
    Sfakianos, John P.
    Tsao, Che-Kai
    Necchi, Andrea
    Montorsi, Francesco
    Gallagher, Emily J.
    Galsky, Matthew D.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2022, 25 (03) : 472 - 478
  • [46] Enzalutamide for the treatment of metastatic castration-resistant prostate cancer
    Rodriguez-Vida, Alejo
    Galazi, Myria
    Rudman, Sarah
    Chowdhury, Simon
    Sternberg, Cora N.
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 3325 - 3339
  • [47] Advancing therapies in metastatic castration-resistant prostate cancer
    Baciarello, Giulia
    Gizzi, Marco
    Fizazi, Karim
    EXPERT OPINION ON PHARMACOTHERAPY, 2018, 19 (16) : 1797 - 1804
  • [48] Is there an optimal treatment sequencing strategy for metastatic castration-resistant prostate cancer?
    Aragon-Ching, Jeanny B.
    FUTURE ONCOLOGY, 2013, 9 (05) : 619 - 622
  • [49] Safety and survival of docetaxel and cabazitaxel in metastatic castration-resistant prostate cancer
    Kreis, Kristine
    Horenkamp-Sonntag, Dirk
    Schneider, Udo
    Zeidler, Jan
    Glaeske, Gerd
    Weissbach, Lothar
    BJU INTERNATIONAL, 2022, 129 (04) : 470 - 479
  • [50] Metastatic Castration-resistant Prostate Cancer: Piling Up the Benefits of Chemotherapy
    Tombal, Bertrand
    EUROPEAN UROLOGY, 2015, 68 (02) : 236 - 237
12345